TRB-051 / Eli Lilly, TRex Bio - LARVOL DELTA

TRexBio Announces Pipeline Progress, Naming TRB-071 as a CD30 Agonist for Immune-Mediated Diseases and Advancement of Lilly-Partnered TRB-051 (Businesswire) - "Preclinical data demonstrated that CD30 agonism via TRB-071 induced Treg activation and expansion, potentially enhancing immune-regulatory capacity and reducing inflammation in colitis models. In non-human primate studies, TRB-071 induced activation and expansion of Tregs with minimal effects on other immune cell populations. TRexBio believes these findings support the potential of TRB-071 as a differentiated approach to restoring immune balance. The company is currently conducting a three-month GLP toxicology study of TRB-071 in cynomolgus monkeys....TRexBio also announced that its collaboration partner Lilly intends to initiate a Phase 2a clinical trial of TRB-051 in lupus with cutaneous involvement in the second half of 2026."

New P2a trial • Preclinical • Cutaneous Lupus Erythematosus • Immunology

TRexBio Announces Collaboration Partner Lilly Has Initiated a Phase 1 Study of TRB-051 for Autoimmune and Inflammatory Diseases (Businesswire) - "TRex Bio, Inc...announced that collaboration partner Eli Lilly and Company ('Lilly') has initiated a Phase 1 first-in-human study of TRB-051, a modulator of immune effector cells, for treatment of autoimmune and inflammatory diseases. The program is one of three under the research collaboration and exclusive worldwide license agreement between TRexBio and Lilly, which leverages TRexBio’s proprietary Deep Biology platform to identify and develop novel therapies for the treatment of immune-mediated diseases. Pursuant to the agreement, TRexBio has earned a double-digit million dollar milestone payment and is eligible to receive more than $1.1 billion on achievement of certain development, regulatory, and commercial milestones across partnered programs....TRB-061 is currently in IND enabling studies, and the company anticipates advancing the program into the clinic in the first half of 2025."

New trial • Trial status • Immunology